Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials

Joanne M. Jeter, Tawnya L. Bowles, Clara Curiel-Lewandrowski, Susan M. Swetter, Fabian V. Filipp, Zalfa A. Abdel-Malek, Larisa J. Geskin, Jerry D. Brewer, Jack L. Arbiser, Jeffrey E. Gershenwald, Emily Y. Chu, John M. Kirkwood, Neil F. Box, Pauline Funchain, David E. Fisher, Kari L. Kendra, Ashfaq A. Marghoob, Suephy C. Chen, Michael E. Ming, Mark R. Albertini & 22 others John T. Vetto, Kim A. Margolin, Sherry L. Pagoto, Jennifer L. Hay, Douglas Grossman, Darrel L. Ellis, Mohammed Kashani-Sabet, Aaron R. Mangold, Svetomir N. Markovic, Kelly C. Nelson, Jennifer G. Powers, June K Robinson, Debjani Sahni, Aleksandar Sekulic, Vernon K. Sondak, Maria L. Wei, Jonathan S. Zager, Robert P. Dellavalle, John A. Thompson, Martin A. Weinstock, Sancy A. Leachman, Pamela B. Cassidy

Research output: Contribution to journalReview article

1 Citations (Scopus)

Abstract

Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.

Original languageEnglish (US)
Pages (from-to)18-44
Number of pages27
JournalCancer
Volume125
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Phase III Clinical Trials
Chemoprevention
Melanoma
Drug Repositioning
Biological Products
Keratinocytes
Research
Research Personnel
Clinical Trials
Morbidity
Carcinoma
Costs and Cost Analysis
Survival
Therapeutics
Neoplasms

Keywords

  • biomarkers
  • chemoprevention
  • human model systems
  • melanoma
  • natural products

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jeter, J. M., Bowles, T. L., Curiel-Lewandrowski, C., Swetter, S. M., Filipp, F. V., Abdel-Malek, Z. A., ... Cassidy, P. B. (2019). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 125(1), 18-44. https://doi.org/10.1002/cncr.31719
Jeter, Joanne M. ; Bowles, Tawnya L. ; Curiel-Lewandrowski, Clara ; Swetter, Susan M. ; Filipp, Fabian V. ; Abdel-Malek, Zalfa A. ; Geskin, Larisa J. ; Brewer, Jerry D. ; Arbiser, Jack L. ; Gershenwald, Jeffrey E. ; Chu, Emily Y. ; Kirkwood, John M. ; Box, Neil F. ; Funchain, Pauline ; Fisher, David E. ; Kendra, Kari L. ; Marghoob, Ashfaq A. ; Chen, Suephy C. ; Ming, Michael E. ; Albertini, Mark R. ; Vetto, John T. ; Margolin, Kim A. ; Pagoto, Sherry L. ; Hay, Jennifer L. ; Grossman, Douglas ; Ellis, Darrel L. ; Kashani-Sabet, Mohammed ; Mangold, Aaron R. ; Markovic, Svetomir N. ; Nelson, Kelly C. ; Powers, Jennifer G. ; Robinson, June K ; Sahni, Debjani ; Sekulic, Aleksandar ; Sondak, Vernon K. ; Wei, Maria L. ; Zager, Jonathan S. ; Dellavalle, Robert P. ; Thompson, John A. ; Weinstock, Martin A. ; Leachman, Sancy A. ; Cassidy, Pamela B. / Chemoprevention agents for melanoma : A path forward into phase 3 clinical trials. In: Cancer. 2019 ; Vol. 125, No. 1. pp. 18-44.
@article{9a987e50e5d54d9887e7b15986b67780,
title = "Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials",
abstract = "Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.",
keywords = "biomarkers, chemoprevention, human model systems, melanoma, natural products",
author = "Jeter, {Joanne M.} and Bowles, {Tawnya L.} and Clara Curiel-Lewandrowski and Swetter, {Susan M.} and Filipp, {Fabian V.} and Abdel-Malek, {Zalfa A.} and Geskin, {Larisa J.} and Brewer, {Jerry D.} and Arbiser, {Jack L.} and Gershenwald, {Jeffrey E.} and Chu, {Emily Y.} and Kirkwood, {John M.} and Box, {Neil F.} and Pauline Funchain and Fisher, {David E.} and Kendra, {Kari L.} and Marghoob, {Ashfaq A.} and Chen, {Suephy C.} and Ming, {Michael E.} and Albertini, {Mark R.} and Vetto, {John T.} and Margolin, {Kim A.} and Pagoto, {Sherry L.} and Hay, {Jennifer L.} and Douglas Grossman and Ellis, {Darrel L.} and Mohammed Kashani-Sabet and Mangold, {Aaron R.} and Markovic, {Svetomir N.} and Nelson, {Kelly C.} and Powers, {Jennifer G.} and Robinson, {June K} and Debjani Sahni and Aleksandar Sekulic and Sondak, {Vernon K.} and Wei, {Maria L.} and Zager, {Jonathan S.} and Dellavalle, {Robert P.} and Thompson, {John A.} and Weinstock, {Martin A.} and Leachman, {Sancy A.} and Cassidy, {Pamela B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cncr.31719",
language = "English (US)",
volume = "125",
pages = "18--44",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Jeter, JM, Bowles, TL, Curiel-Lewandrowski, C, Swetter, SM, Filipp, FV, Abdel-Malek, ZA, Geskin, LJ, Brewer, JD, Arbiser, JL, Gershenwald, JE, Chu, EY, Kirkwood, JM, Box, NF, Funchain, P, Fisher, DE, Kendra, KL, Marghoob, AA, Chen, SC, Ming, ME, Albertini, MR, Vetto, JT, Margolin, KA, Pagoto, SL, Hay, JL, Grossman, D, Ellis, DL, Kashani-Sabet, M, Mangold, AR, Markovic, SN, Nelson, KC, Powers, JG, Robinson, JK, Sahni, D, Sekulic, A, Sondak, VK, Wei, ML, Zager, JS, Dellavalle, RP, Thompson, JA, Weinstock, MA, Leachman, SA & Cassidy, PB 2019, 'Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials' Cancer, vol. 125, no. 1, pp. 18-44. https://doi.org/10.1002/cncr.31719

Chemoprevention agents for melanoma : A path forward into phase 3 clinical trials. / Jeter, Joanne M.; Bowles, Tawnya L.; Curiel-Lewandrowski, Clara; Swetter, Susan M.; Filipp, Fabian V.; Abdel-Malek, Zalfa A.; Geskin, Larisa J.; Brewer, Jerry D.; Arbiser, Jack L.; Gershenwald, Jeffrey E.; Chu, Emily Y.; Kirkwood, John M.; Box, Neil F.; Funchain, Pauline; Fisher, David E.; Kendra, Kari L.; Marghoob, Ashfaq A.; Chen, Suephy C.; Ming, Michael E.; Albertini, Mark R.; Vetto, John T.; Margolin, Kim A.; Pagoto, Sherry L.; Hay, Jennifer L.; Grossman, Douglas; Ellis, Darrel L.; Kashani-Sabet, Mohammed; Mangold, Aaron R.; Markovic, Svetomir N.; Nelson, Kelly C.; Powers, Jennifer G.; Robinson, June K; Sahni, Debjani; Sekulic, Aleksandar; Sondak, Vernon K.; Wei, Maria L.; Zager, Jonathan S.; Dellavalle, Robert P.; Thompson, John A.; Weinstock, Martin A.; Leachman, Sancy A.; Cassidy, Pamela B.

In: Cancer, Vol. 125, No. 1, 01.01.2019, p. 18-44.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Chemoprevention agents for melanoma

T2 - A path forward into phase 3 clinical trials

AU - Jeter, Joanne M.

AU - Bowles, Tawnya L.

AU - Curiel-Lewandrowski, Clara

AU - Swetter, Susan M.

AU - Filipp, Fabian V.

AU - Abdel-Malek, Zalfa A.

AU - Geskin, Larisa J.

AU - Brewer, Jerry D.

AU - Arbiser, Jack L.

AU - Gershenwald, Jeffrey E.

AU - Chu, Emily Y.

AU - Kirkwood, John M.

AU - Box, Neil F.

AU - Funchain, Pauline

AU - Fisher, David E.

AU - Kendra, Kari L.

AU - Marghoob, Ashfaq A.

AU - Chen, Suephy C.

AU - Ming, Michael E.

AU - Albertini, Mark R.

AU - Vetto, John T.

AU - Margolin, Kim A.

AU - Pagoto, Sherry L.

AU - Hay, Jennifer L.

AU - Grossman, Douglas

AU - Ellis, Darrel L.

AU - Kashani-Sabet, Mohammed

AU - Mangold, Aaron R.

AU - Markovic, Svetomir N.

AU - Nelson, Kelly C.

AU - Powers, Jennifer G.

AU - Robinson, June K

AU - Sahni, Debjani

AU - Sekulic, Aleksandar

AU - Sondak, Vernon K.

AU - Wei, Maria L.

AU - Zager, Jonathan S.

AU - Dellavalle, Robert P.

AU - Thompson, John A.

AU - Weinstock, Martin A.

AU - Leachman, Sancy A.

AU - Cassidy, Pamela B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.

AB - Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.

KW - biomarkers

KW - chemoprevention

KW - human model systems

KW - melanoma

KW - natural products

UR - http://www.scopus.com/inward/record.url?scp=85054331583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054331583&partnerID=8YFLogxK

U2 - 10.1002/cncr.31719

DO - 10.1002/cncr.31719

M3 - Review article

VL - 125

SP - 18

EP - 44

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 Jan 1;125(1):18-44. https://doi.org/10.1002/cncr.31719